In this cohort, CYP2A6 genotype predicted P450 2A6 activity, measured as the urinary ratio of 3′-hydroxycotinine to cotinine, and the risk of lung cancer was 30% lower for predicted poor metabolizers compared with other groups (Fig. 6). The gene discussed is CYP2A6; the disease is lung carcinoma.